![The F-35’s future: Can the fifth-gen fighter withstand political, technological headwinds? [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/04/240401_f35_clouds_8270083-scaled-e1711999276822.jpg?#)
ASCO: AstraZeneca, Daiichi flex Enhertu's muscles in first-line breast cancer as they drop new phase 3 gastric cancer data
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu looks poised to reach newly diagnosed patients, with efficacy data that live up to the pair’s previous “highly statistically significant” description.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu looks poised to reach newly diagnosed patients, with efficacy data that live up to the pair’s previous “highly statistically significant” description.
